Core Viewpoint - The pharmaceutical sector is experiencing a rebound, with the pharmaceutical ETF (159929) rising by 0.8% and a total trading volume exceeding 86 million yuan, indicating strong investor interest and capital inflow [1]. Group 1: Market Performance - The pharmaceutical ETF (159929) has seen a capital inflow of over 320 million yuan in the last 20 days, with 15 of those days showing increased funding [1]. - The latest financing balance has surged to over 75 million yuan, reflecting continued leverage in the market [1]. - Major stocks within the ETF, such as Mindray Medical and United Imaging, have shown positive performance, with several stocks rising over 1% [4]. Group 2: Sector Analysis - The report highlights a shift in focus within the pharmaceutical sector towards innovative fields such as AI healthcare and medical robotics, moving away from previously strong areas like brain-computer interfaces [3]. - The CRO (Contract Research Organization) sector has also shown some performance, driven by market sentiment and expectations of turning points in the industry [3]. - The top three investment directions identified for 2026 include BD 2.0, small nucleic acids, and supply chain (CXO and upstream), emphasizing the importance of innovation and international expansion [5]. Group 3: Company Highlights - Key companies in the ETF include WuXi AppTec, with an estimated weight of 10.77%, and Hengrui Medicine, with a weight of 9.41%, both of which are significant players in the pharmaceutical industry [2]. - Tempus AI reported a revenue of approximately 1.27 billion USD for 2025, marking an 83% year-on-year growth, showcasing the commercial viability of AI in healthcare [6]. - NVIDIA and Eli Lilly announced a partnership to establish an AI innovation lab, investing up to 1 billion USD over five years to address challenges in drug discovery and development [5].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund, managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks for the fourth quarter of 2025 [1][4]. Fund Performance - As of December 31, 2025, the total size of funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The net value growth rate for Class A shares of the China Europe Medical Health Mixed Fund was -14.81%, while the benchmark return was -8.21% [1]. - Class C shares experienced a net value growth rate of -14.98%, also underperforming the benchmark [1]. Holdings Overview - The top ten holdings of the China Europe Medical Health Mixed Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. - The largest holding, WuXi AppTec, accounted for 10.11% of the fund's net value, with a market value of approximately 2.724 billion yuan [2]. Market Context - The CSI Medical Index fell by 12.7% in the fourth quarter of 2025, underperforming the Shanghai and Shenzhen 300 Index, which declined by only 0.2% [3]. - There was significant differentiation within sub-sectors, with the innovative industry chain entering a correction phase after previous gains, while traditional Chinese medicine and pharmaceutical commerce showed relative stability [3]. Future Outlook - Looking ahead to the first quarter of 2026, improvements in global liquidity are expected to boost investment and financing in innovative drugs, supported by domestic policy enhancements [4]. - The innovative drug and medical device industry chain is anticipated to maintain high levels of activity, with several key domestic drugs approaching critical data readout points [5]. - The CXO sector is expected to benefit from a recovery in biotechnology financing, leading to improved order conditions [5]. - The pharmaceutical sector is projected to experience structural trends driven by macroeconomic improvements, supportive industry policies, and ongoing innovation [5].

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. has successfully issued its first phase of technology innovation bonds for 2026, raising funds for debt repayment and working capital [1][2]. Group 1 - The company received approval from the board of directors and shareholders for the issuance of non-financial corporate debt financing tools on April 22, 2025, and May 19, 2025, respectively [1]. - The company was granted a registration notice by the China Interbank Market Dealers Association on September 16, 2025, allowing for a medium-term note registration quota of RMB 3 billion, valid for two years [2]. - The first phase of the technology innovation bonds was issued on January 19, 2026, with the total funds raised credited to the company on January 20, 2026 [2]. Group 2 - The funds raised from this bond issuance will be used to repay existing debts and supplement working capital [2]. - As of the date of the announcement, the company is not classified as a dishonest entity [2].

2025年1-11月，化学原料和化学制品制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从 2011年起，规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万 元）为27102个，和上年同期相比，增加了815个，同比增长3.1%，占工业总企业的比重为5.15%。 2016-2025年1-11月化学原料和化学制品制造业企业数统计图 数据来源：国家统计局，智研咨询整理 上市公司：海南海药（000566），东北制药（000597），亚太实业（000691），通化金马（000766）， 北大医药（000788），力生制药（002393），海普瑞（002399），科伦药业（002422），杭氧股份 （002430），长江健康（002435），誉衡药业（002437），华软科技（002453） 相关报告：智研咨询发布的《2026-2032年中国有机化学原料制造行业市场分析研究及产业前景研判报 告》 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务 ...

2026年度第一期科技创新债券发行结果的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）《关于公司发行非金融 企业债务融资工具的议案》已于2025年4月22日经公司第八届董事会第六次会议 审议通过，并于2025年5月19日经公司2024年年度股东大会审议批准。相关董事 会和股东大会决议公告详见2025年4月24日和2025年5月20日的《证券时报》、 《上海证券报》、《证券日报》和《中国证券报》以及公司指定信息披露网站 巨潮资讯网（http://www.cninfo.com.cn）。 公司于2025年9月18日收到中国银行间市场交易商协会（以下简称"交易商 协会"）于2025年9月16日下发的《接受注册通知书》（以下简称《通知书》） （中市协注〔2025〕MTN904号），交易商协会同意接受公司中期票据注册， 中期票据注册额度为人民币30亿元，注册额度自《通知书》落款之日起2年内有 效。 公司于近日获悉，公司2026年度第一期科技创新债券于2026年1月19日发行， 募集资金已于2026年1月20日全额到账。 证券 ...

Core Viewpoint - The article discusses the IPO application of Xiansheng Zaiming Pharmaceutical Co., Ltd. and its strategic focus on the oncology innovation drug sector, highlighting the company's financial performance, market positioning, and future growth potential through the separation from its parent company [1][2][9]. Financial Performance - In 2023, 2024, and the first nine months of 2025, the company achieved revenues of 1.522 billion, 1.296 billion, and 1.238 billion respectively, but remained in a loss position due to high R&D and sales expenses [2][8]. - The net losses recorded were 336 million, 506 million, and 303 million for the same periods, indicating ongoing financial pressure from high investment needs [8][11]. Market Positioning - Xiansheng Zaiming has established itself as a new player in China's oncology innovation drug industry, with five commercialized innovative drugs contributing over 90% of total revenue [5][6]. - The company has formed multiple licensing collaborations with potential total transaction values exceeding 2.8 billion, positioning it as one of the most active biopharmaceutical companies in China for licensing transactions [6][9]. R&D and Commercialization Strategy - The company maintains a high R&D investment intensity, with R&D costs of 831 million, 708 million, and 512 million for 2023, 2024, and the first nine months of 2025, respectively, representing over 50% of revenue in the earlier years [8][11]. - A sales and marketing team of over 1,200 has been established, with sales and distribution expenses exceeding 40% of revenue during the reporting periods [8][11]. Strategic Separation - The decision to spin off the oncology business is part of a broader strategy for Xiansheng Pharmaceutical to transition towards an innovation-driven model, allowing for a more focused approach to R&D and commercialization in oncology [9][10]. - The spin-off is expected to create a dedicated financing platform for oncology innovation drugs, attracting long-term investment and providing organizational support for sustained R&D [9][10]. Future Growth Potential - The company has over 60 innovative drug pipelines, with six candidate drugs in NDA or key clinical stages, indicating a robust future growth trajectory [9][10]. - The successful launch of its innovative drug, Kewike®, in June 2025, is expected to contribute significantly to market revenue, showcasing the company's potential in the CNS field [10][11].

Core Viewpoint - The company, Xiansheng Zaiming Pharmaceutical Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to establish a dedicated financing platform for its oncology business, which is currently under the parent company, Xiansheng Pharmaceutical [1][8]. Financial Performance - The company reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively [2]. - Despite stable revenue growth, the company remains in a loss position due to high R&D and sales expenses, recording net losses of 336 million yuan, 506 million yuan, and 303 million yuan for the same periods [6]. - R&D costs were 831 million yuan, 708 million yuan, and 512 million yuan for 2023, 2024, and the first nine months of 2025, with R&D expenses exceeding 50% of revenue in 2023 and 2024 [5]. Business Strategy - The company focuses on the development and commercialization of innovative oncology drugs, having five commercialized products that contribute over 90% of total revenue [4]. - The split from Xiansheng Pharmaceutical allows the company to optimize its financial structure while maintaining absolute control over the oncology business [2]. - The company has established a sales and marketing team of over 1,200 people to enhance product marketization [5]. Market Position and Collaborations - Xiansheng Zaiming has engaged in multiple licensing collaborations with companies like AbbVie, Ipsen, and NextCure, with a potential total transaction value exceeding 2.8 billion USD [5]. - The company ranks first in the number of oncology asset transactions and fourth in total value among Chinese biopharmaceutical companies [5]. Challenges and Considerations - The company faces challenges related to high market channel concentration, with the top five customers accounting for over 65% of revenue [11]. - The overall gross margin has decreased from approximately 72% to 68.1%, attributed to structural adjustments in revenue sources and product mix [12]. - The company has set a timeline for its IPO process, needing to submit its application by June 2027 and complete the listing by the end of 2028, with penalties for delays [12].

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Group 1 - The company has reported that it is currently selling its ergotamine products through various platforms, including WeChat Mini Programs, Tmall, and JD.com [2] - The company has developed a strategic plan for the health and wellness sector and is making steady progress in its implementation [2]